Intradermal Allergen Immunotherapy for Allergic Rhinitis: Current Evidence
Issued Date
2022-08-01
Resource Type
eISSN
20754426
Scopus ID
2-s2.0-85137386844
Journal Title
Journal of Personalized Medicine
Volume
12
Issue
8
Rights Holder(s)
SCOPUS
Bibliographic Citation
Journal of Personalized Medicine Vol.12 No.8 (2022)
Suggested Citation
Atipas K., Kanjanawasee D., Tantilipikorn P. Intradermal Allergen Immunotherapy for Allergic Rhinitis: Current Evidence. Journal of Personalized Medicine Vol.12 No.8 (2022). doi:10.3390/jpm12081341 Retrieved from: https://repository.li.mahidol.ac.th/handle/20.500.14594/85644
Title
Intradermal Allergen Immunotherapy for Allergic Rhinitis: Current Evidence
Author(s)
Author's Affiliation
Other Contributor(s)
Abstract
Allergic rhinitis (AR) is an immunoglobulin E (IgE)-mediated inflammatory disease that is induced by allergen introduction to the nasal mucosa, which triggers an inflammatory response. The current treatments for AR include allergen avoidance and pharmacotherapy; however, allergen-specific immunotherapy (AIT) is the only treatment that can be employed to modify immunologic responses and to achieve a cure for allergic diseases. The current standard routes of AIT administration are the subcutaneous and sublingual routes. Alternatively, the dermis contains a high density of dermal dendritic cells that act as antigen-presenting cells, so intradermal administration may confer added advantages and increase the efficacy of AIT. Moreover, intradermal immunotherapy (IDIT) may facilitate a reduction in the allergen dosage and a shortening of the treatment duration. The aim of this review was to search and evaluate the current evidence specific to IDIT, including its modified formulations, such as allergoids and peptides. The results of this review reveal conflicting evidence that suggests that the overall benefit of IDIT remains unclear. As such, further clinical trials are needed to establish the clinical utility of IDIT, and to determine the optimal treatment-related protocols.